Chung-Che J. Chang, MD, PhD, FCAP

Pathologist

Cancer Research

Expertise of Chung-Che J. Chang, MD, PhD, FCAP

Education: National Yan-Ming Medical College, Shipai, Beitou District, Taipei, Taiwan
Residency: Metrohealth Medical Center, Cleveland, OH
Board Certifications: American Board of Pathology

Publications

Getting Your Laboratory on Track With Neurotrophic Receptor Tyrosine Kinase

2023, ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

View publication for "Getting Your Laboratory on Track With Neurotrophic Receptor Tyrosine Kinase"
Mast cell sarcoma: clinicopathologic and molecular analysis of 10 new cases and review of literature

2022, MODERN PATHOLOGY

View publication for "Mast cell sarcoma: clinicopathologic and molecular analysis of 10 new cases and review of literature"
Clinicopathologic Features of Lymphoproliferative Neoplasms Involving the Liver

2022, MEDICINA-LITHUANIA

View publication for "Clinicopathologic Features of Lymphoproliferative Neoplasms Involving the Liver"

More sources loaded
Case Report: Phenotypic Switch in High-Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements: A Potential Mechanism of Therapeutic Resistance in Lymphoma?

2021, FRONTIERS IN ONCOLOGY

View publication for "Case Report: Phenotypic Switch in High-Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements: A Potential Mechanism of Therapeutic Resistance in Lymphoma?"
Mutational profiling of myeloid neoplasms associated genes may aid the diagnosis of acute myeloid leukemia with myelodysplasia-related changes

2021, LEUKEMIA RESEARCH

View publication for "Mutational profiling of myeloid neoplasms associated genes may aid the diagnosis of acute myeloid leukemia with myelodysplasia-related changes"
Adverse Overall Survival Impact of PD-L1 Positivity in Patients With KRAS G12C Mutation Is Abolished by the Immunotherapy

2021, CLINICAL LUNG CANCER

View publication for "Adverse Overall Survival Impact of PD-L1 Positivity in Patients With KRAS G12C Mutation Is Abolished by the Immunotherapy"
Comparison of Myeloablative versus Reduced-Intensity Conditioning Regimens in Allogeneic Stem Cell Transplantation Recipients with Acute Myelogenous Leukemia with Measurable Residual Disease-Negative Disease at the Time of Transplantation: A Retrospective Cohort Study

2021, TRANSPLANTATION AND CELLULAR THERAPY

View publication for "Comparison of Myeloablative versus Reduced-Intensity Conditioning Regimens in Allogeneic Stem Cell Transplantation Recipients with Acute Myelogenous Leukemia with Measurable Residual Disease-Negative Disease at the Time of Transplantation: A Retrospective Cohort Study"
Adverse Impact of DNA Methylation Regulatory Gene Mutations on the Prognosis of AML Patients in the 2017 ELN Favorable Risk Group, Particularly Those Defined by NPM1 Mutation

2021, DIAGNOSTICS

View publication for "Adverse Impact of DNA Methylation Regulatory Gene Mutations on the Prognosis of AML Patients in the 2017 ELN Favorable Risk Group, Particularly Those Defined by NPM1 Mutation"
Local ALK-Positive Histiocytosis With Unusual Morphology and Novel TRIM33-ALK Gene Fusion

2020, INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY

View publication for "Local ALK-Positive Histiocytosis With Unusual Morphology and Novel TRIM33-ALK Gene Fusion"
Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma

2020, CLINICAL LUNG CANCER

View publication for "Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma"

More Publication Information

Associated Clinical Trials for Chung-Che J. Chang, MD, PhD, FCAP

PD-L1 expression in lung adenocarcinomas with different subtypes of KRAS mutations and its clinical significance

This study is not currently enrolling.

Associated Conditions: Lung Cancer

Research Area: Cancer Research

The purpose of this study is to evaluate if the degree of PD-L1 expression and/or certain subtype(s) of KRAS mutation which may impact outcomes (survivals and/or pattern of metastasis) of lung...

More clinical trials loaded

Chung-Che J. Chang, MD, PhD, FCAP

Expertise of Chung-Che J. Chang, MD, PhD, FCAP

Associated Clinical Trials for Chung-Che J. Chang, MD, PhD, FCAP

PD-L1 expression in lung adenocarcinomas with different subtypes of KRAS mutations and its clinical significance